GPT Healthcare informs about audio recording of conference call

GPT Healthcare Ltd. | Hospital & Healthcare Services | Healthcare | BSE: 544131 | NSE: GPTHEALTH

15 Nov 2024 Evaluate

In compliance with Regulation 30 read with Part A of Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, GPT Healthcare has informed that the Company Participated in a Conference Call with Investors on Thursday, November 14, 2024 at 5.00 PM (IST) to discuss the financial performance of the Company for the 2nd quarter and half year ended September 30, 2024. No unpublished price sensitive information was shared / discussed in the meeting. The link for Audio recording: https://ilshospitals.com/wp-content/uploads/2024/11/Call_Transcript.mp3 The same has been uploaded at the website of the Company.

The above information is a part of company’s filings submitted to BSE.

Peers

Company Name	CMP
Manipal Health Enter	716.15
Apollo Hospital Ent.	8850.00
Fortis Healthcare	887.30
Max Healthcare Inst.	1037.20
Narayana Hrudayalay.	1867.35
View more..

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.